WO2003082330A1 - Therapeutic drug using antibody-presenting hollow protein nanoparticles and hollow protein nanoparticles - Google Patents

Therapeutic drug using antibody-presenting hollow protein nanoparticles and hollow protein nanoparticles Download PDF

Info

Publication number: WO2003082330A1
Authority: WO; WIPO (PCT)
Prior art keywords: antibody; protein nanoparticles; drug; hollow protein; hollow
Prior art date: 2002-03-29
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

PCT/JP2003/003694

Other languages

English (en)

French (fr)

Inventor

Shunichi Kuroda

Katsuyuki Tanizawa

Akihiko Kondo

Masakazu Ueda

Masaharu Seno

Toshihide Okajima

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Japan Science and Technology Agency

Original Assignee

Japan Science and Technology Agency

Japan Science and Technology Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-03-29

Filing date

2003-03-26

Publication date

2003-10-09

2003-03-26 Application filed by Japan Science and Technology Agency, Japan Science and Technology Corp filed Critical Japan Science and Technology Agency

2003-03-26 Priority to KR1020047015430A priority Critical patent/KR100635870B1/ko

2003-03-26 Priority to EP03715409.3A priority patent/EP1491210B1/en

2003-03-26 Priority to US10/509,249 priority patent/US7951379B2/en

2003-10-09 Publication of WO2003082330A1 publication Critical patent/WO2003082330A1/ja

2004-09-29 Anticipated expiration legal-status Critical

Status Ceased legal-status Critical Current

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5184—Virus capsids or envelopes enclosing drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/44—Antibodies bound to carriers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10123—Virus like particles [VLP]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Zoology (AREA)
Epidemiology (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Nanotechnology (AREA)
Microbiology (AREA)
Virology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Mycology (AREA)
Botany (AREA)
Gastroenterology & Hepatology (AREA)
Medical Informatics (AREA)
Crystallography & Structural Chemistry (AREA)
Cell Biology (AREA)
Optics & Photonics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Peptides Or Proteins (AREA)

PCT/JP2003/003694 2002-03-29 2003-03-26 Therapeutic drug using antibody-presenting hollow protein nanoparticles and hollow protein nanoparticles Ceased WO2003082330A1 (en)

Priority Applications (3)

Application Number	Priority Date	Filing Date	Title
KR1020047015430A KR100635870B1 (ko)	2002-03-29	2003-03-26	항체를 제시하는 단백질 중공 나노입자를 사용하는치료약제 및 단백질 중공 나노입자
EP03715409.3A EP1491210B1 (en)	2002-03-29	2003-03-26	Therapeutic drug using antibody-presenting hollow protein nanoparticles and hollow protein nanoparticles
US10/509,249 US7951379B2 (en)	2002-03-29	2003-03-26	Hollow nanoparticle of NBsAg large protein for drug delivery

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
JP2002097424		2002-03-29
JP2002-97424		2002-03-29
JP2003045088A JP4212921B2 (ja)	2002-03-29	2003-02-21	抗体を提示するタンパク質中空ナノ粒子を用いる治療薬剤およびタンパク質中空ナノ粒子
JP2003-45088		2003-02-21

Publications (1)

Publication Number	Publication Date
WO2003082330A1 true WO2003082330A1 (en)	2003-10-09

Family

ID=28677594

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PCT/JP2003/003694 Ceased WO2003082330A1 (en)	2002-03-29	2003-03-26	Therapeutic drug using antibody-presenting hollow protein nanoparticles and hollow protein nanoparticles

Country Status (5)

Country	Link
US (1)	US7951379B2 (ja)
EP (1)	EP1491210B1 (ja)
JP (1)	JP4212921B2 (ja)
KR (1)	KR100635870B1 (ja)
WO (1)	WO2003082330A1 (ja)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2005049824A1 (ja) *	2003-11-21	2005-06-02	Japan Science And Technology Agency	生体構造認識部位を提示する中空ナノ粒子およびその生産方法、並びにその利用
WO2007037273A1 (ja) *	2005-09-28	2007-04-05	National University Corporation Kobe University	細胞膜透過ペプチドを提示したナノ粒子による細胞への物質導入
WO2008018555A1 (en) *	2006-08-11	2008-02-14	National University Corporation Okayama University	HBsAg PARTICLE HAVING LOW ANTIGENICITY AND METHOD FOR PRODUCTION THEREOF
WO2013147232A1 (ja) *	2012-03-30	2013-10-03	国立大学法人名古屋大学	樹状細胞表面タンパク質に対する抗体を有するバイオナノカプセル

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20070059746A1 (en) *	2005-09-14	2007-03-15	Japan Science And Technology Agency	Substance carrier using hollow nanoparticle of hepatitis B virus protein and liposome, and method of introducing substance into cell
LT2481402T (lt) *	2007-03-07	2018-10-25	Abraxis Bioscience, Llc	Nanodalelė, apimanti rapamiciną ir albuminą, kaip priešvėžinį agentą
EP2262489A2 (en) *	2008-02-28	2010-12-22	Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts	Hollow nanoparticles and uses thereof
JP2010096677A (ja) *	2008-10-17	2010-04-30	Toray Ind Inc	抗体／抗原結合能を有する高感度免疫学測定用ナノ粒子
ES2845212T3 (es)	2009-04-13	2021-07-26	Inst Nat Sante Rech Med	Partículas de HPV y usos de las mismas
US9700639B2 (en)	2012-02-07	2017-07-11	Aura Biosciences, Inc.	Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
EP4059521A1 (en)	2013-09-18	2022-09-21	Aura Biosciences, Inc.	Virus-like particle conjugates for diagnosis and treatment of tumors
CN108473950A (zh)	2015-10-30	2018-08-31	美国政府卫生与公众服务部	靶向癌症治疗
CA3059882A1 (en)	2017-04-12	2018-10-18	Aura Biosciences, Inc.	Targeted combination therapy
MX2022007881A (es)	2019-12-23	2022-07-19	Mitsubishi Tanabe Pharma Corp	Proteina f mutante del virus sincitial respiratorio (rsv) y usos de la misma.
JP7787563B2 (ja) *	2022-01-12	2025-12-17	株式会社ビークル	新型コロナウイルスの検出に使用可能な融合タンパク質およびその用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1994006929A1 (en) *	1992-09-17	1994-03-31	Merck Patent Gmbh	Small cell lung carcinoma specific antibody and antigen
WO1996001126A1 (en) *	1994-07-06	1996-01-18	Immunomedics, Inc.	Multi-stage cascade boosting vaccine
EP0706799A2 (en) *	1994-09-16	1996-04-17	MERCK PATENT GmbH	Immunoconjugates II
WO2001064930A1 (en) *	2000-02-28	2001-09-07	Japan Science And Technology Corporation	Protein hollow nano particles, transporter with the use of the same and method of introducing substance into cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH08504088A (ja)	1992-09-17	1996-05-07	メルクパテントゲゼルシャフトミットベシュレンクテルハフトング	腫瘍特異性抗体および抗原
US7354587B1 (en)	1994-07-06	2008-04-08	Immunomedics, Inc.	Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines
CA2240834C (en)	1995-12-22	2013-12-03	Immunomedics, Inc.	Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines
AU3916997A (en) *	1996-08-19	1998-03-06	Vivorx Pharmaceuticals, Inc.	Methods for the production of protein particles useful for delivery of pharmacological agents
CA2318981A1 (en) *	1998-02-09	1999-08-12	Genzyme Corporation	Nucleic acid delivery vehicles

2003
- 2003-02-21 JP JP2003045088A patent/JP4212921B2/ja not_active Expired - Lifetime
- 2003-03-26 US US10/509,249 patent/US7951379B2/en not_active Expired - Fee Related
- 2003-03-26 WO PCT/JP2003/003694 patent/WO2003082330A1/ja not_active Ceased
- 2003-03-26 EP EP03715409.3A patent/EP1491210B1/en not_active Expired - Lifetime
- 2003-03-26 KR KR1020047015430A patent/KR100635870B1/ko not_active Expired - Fee Related

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1994006929A1 (en) *	1992-09-17	1994-03-31	Merck Patent Gmbh	Small cell lung carcinoma specific antibody and antigen
WO1996001126A1 (en) *	1994-07-06	1996-01-18	Immunomedics, Inc.	Multi-stage cascade boosting vaccine
EP0706799A2 (en) *	1994-09-16	1996-04-17	MERCK PATENT GmbH	Immunoconjugates II
WO2001064930A1 (en) *	2000-02-28	2001-09-07	Japan Science And Technology Corporation	Protein hollow nano particles, transporter with the use of the same and method of introducing substance into cells

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AHMAD I. ET AL.: "Antibody-mediated specific binding and cytotoxicity of liposome-entrapped doxorubicin to lung cancer cells in vitro", CANCER RES., vol. 52, no. 17, 1992, pages 4817 - 4820, XP002959035 *
NAKAMURA Y. ET AL.: "Development of novel whole-cell immunoadsorbents by yeast surface display of the IgG-binding domain", APPL. MICROBIOL. BIOTECHNOL., vol. 57, no. 4, 2001, pages 500 - 505, XP002969302 *
See also references of EP1491210A4 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2005049824A1 (ja) *	2003-11-21	2005-06-02	Japan Science And Technology Agency	生体構造認識部位を提示する中空ナノ粒子およびその生産方法、並びにその利用
WO2007037273A1 (ja) *	2005-09-28	2007-04-05	National University Corporation Kobe University	細胞膜透過ペプチドを提示したナノ粒子による細胞への物質導入
WO2008018555A1 (en) *	2006-08-11	2008-02-14	National University Corporation Okayama University	HBsAg PARTICLE HAVING LOW ANTIGENICITY AND METHOD FOR PRODUCTION THEREOF
JP5147697B2 (ja) *	2006-08-11	2013-02-20	国立大学法人岡山大学	低抗原性のＨＢｓＡｇ粒子及びその作製法
WO2013147232A1 (ja) *	2012-03-30	2013-10-03	国立大学法人名古屋大学	樹状細胞表面タンパク質に対する抗体を有するバイオナノカプセル
JP5458286B1 (ja) *	2012-03-30	2014-04-02	国立大学法人名古屋大学	樹状細胞表面タンパク質に対する抗体を有するバイオナノカプセル

Also Published As

Publication number	Publication date
EP1491210A4 (en)	2010-10-13
JP4212921B2 (ja)	2009-01-21
KR100635870B1 (ko)	2006-10-18
EP1491210A1 (en)	2004-12-29
US20060088536A1 (en)	2006-04-27
US7951379B2 (en)	2011-05-31
JP2004002313A (ja)	2004-01-08
EP1491210B1 (en)	2013-06-19
KR20040105815A (ko)	2004-12-16

Legal Events

Date	Code	Title	Description
2003-10-09	AK	Designated states	Kind code of ref document: A1 Designated state(s): KR US
2003-10-09	AL	Designated countries for regional patents	Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR
2003-11-06	DFPE	Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
2003-12-03	121	Ep: the epo has been informed by wipo that ep was designated in this application
2004-09-24	WWE	Wipo information: entry into national phase	Ref document number: 1020047015430 Country of ref document: KR
2004-09-28	ENP	Entry into the national phase	Ref document number: 2006088536 Country of ref document: US Kind code of ref document: A1
2004-09-28	WWE	Wipo information: entry into national phase	Ref document number: 10509249 Country of ref document: US
2004-10-15	WWE	Wipo information: entry into national phase	Ref document number: 2003715409 Country of ref document: EP
2004-12-16	WWP	Wipo information: published in national office	Ref document number: 1020047015430 Country of ref document: KR
2004-12-29	WWP	Wipo information: published in national office	Ref document number: 2003715409 Country of ref document: EP
2006-04-27	WWP	Wipo information: published in national office	Ref document number: 10509249 Country of ref document: US

Publication	Publication Date	Title
White et al.	2004	Polyomaviruses and human cancer: molecular mechanisms underlying patterns of tumorigenesis
DE60138641D1 (de)	2009-06-18	Herstellung von mikrokügelchen
CY1112110T1 (el)	2015-11-04	Κυκλικο μοριο dna το οποιο διαθετει μια συμβατικη αφετηρια αντιγραφης, η διαδικασια παρασκευης του και η χρηση του στην γονιδιακη θεραπεια
WO2004084939A8 (en)	2005-06-09	Hiv-peptide-carrier-conjugates
CY1110585T1 (el)	2015-04-29	ΣΥΣΚΕΥΑΣΙΑ (ΠΑΚΕΤΑΡΙΣΜΑ) ΑΝΟΣΟΔΙΕΓΕΡΤIΚΩΝ CpG ΕΝΤΟΣ ΟΜΟΙΑΖΟΝΤΩΝ ΜΕ ΙΟ ΣΩΜΑΤΙΩΝ: ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΚΑΙ ΧΡΗΣΗ
BRPI0412845A (pt)	2006-09-26	herpes-vìrus, uso de um vìrus, composição farmacêutica, e, método de tratamento de um tumor em um indivìduo em necessidade do mesmo
WO2004016733A3 (en)	2006-03-16	Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
CY1113875T1 (el)	2016-06-22	Βελτιστοποιημενη εκφραση hpv 58 l1 σε ζυμομυκητα
EP1775342A4 (en)	2007-11-07	ANTITUM-AGENT WITH MINUS STRAND RNA VIRUS
EP1262555A4 (en)	2008-01-02	HIGH PROTEIN NANOPARTICLES, BASED TRANSPORTERS AND METHOD FOR INTRODUCING SUBSTANCES IN CELLS
WO2003072711A3 (en)	2003-11-06	Method of using modified oligonucleotides for hepatic delivery
WO2007067730A3 (en)	2007-11-01	Human monoclonal antibodies to protein tyrosine kinase 7 ( ptk7 ) and their use
DE50310081D1 (de)	2008-08-14	Tumorspezifische erkennungsmoleküle
AR026946A1 (es)	2003-03-05	Osteoprotegerina/receptores de factores de necrosis de tumores
WO2008034388A8 (en)	2009-07-09	Virus-like particles of capsid proteins from human papillomavirus type 16/58/18/6/11 and the method for preparation and the uses thereof
WO2004031231A3 (en)	2004-07-08	Genes and polypeptides relating to prostate cancers
JP2003503319A5 (ja)	2007-08-09
CY1107431T1 (el)	2012-12-19	Σωματιδια για γoνιδιακη θεραπεια
WO2003082345A1 (en)	2003-10-09	Drugs comprising protein forming hollow nanoparticles and therapeutic substance to be transferred into cells fused therewith
EP1712243A4 (en)	2007-04-11	GENE THERAPY FOR TUMOR USING A NEGATIVE CHAIN RNA VIRAL VECTOR ENCODING AN IMMUNOSTIMULATORY CYTOKINE
WO2004013313A3 (en)	2004-10-28	Antisense nucleic acids
Iannazzo et al.	2024	Graphene-based materials as nanoplatforms for antiviral therapy and prophylaxis
WO2005113005A3 (en)	2006-06-22	Transcutaneous and/or transdermal transport of materials
ATE411044T1 (de)	2008-10-15	Monozyte-spezifisches teilchenförmiges verabreichungsvehikel
Ma et al.	2021	Three Alternative Treatment Protocols for the Efficient Inactivation of Potato Virus X